Home LiteratureArticle Details
PMID: 11481463 Published · ppublish English Comment Journal Article

Progress in cancer vaccines by enhanced self-presentation.

Proceedings of the National Academy of Sciences of the United States of America ·Vol. 98 ·No. 16 ·2001-07-31 ·Pages 8933-5

Riddell SR

Abstract

暂无摘要

MeSH Terms
Antigen-Presenting Cells/immunology Antigens, CD/immunology CD4-Positive T-Lymphocytes/immunology CD8-Positive T-Lymphocytes/immunology Cancer Vaccines/immunology Humans
Chemicals
Antigens, CD Cancer Vaccines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Riddell S R
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. sriddell@fhcrc.org
References (47)
47 references, click to expand
  1. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 PMID: 9448305
  2. Flt3 ligand induces tumor regression and antitumor immune responses in vivo.
    Nat Med. 1997 Jun;3(6):625-31 PMID: 9176488
  3. The duration of antigenic stimulation determines the fate of naive and effector T cells.
    Immunity. 1998 Jan;8(1):89-95 PMID: 9462514
  4. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
    Nat Med. 1998 Mar;4(3):321-7 PMID: 9500606
  5. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nat Med. 1998 Mar;4(3):328-32 PMID: 9500607
  6. Dendritic cells and the control of immunity.
    Nature. 1998 Mar 19;392(6673):245-52 PMID: 9521319
  7. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
    J Immunol. 1998 Jan 15;160(2):643-51 PMID: 9551898
  8. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens.
    J Exp Med. 1998 May 18;187(10):1549-53 PMID: 9584133
  9. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.
    J Exp Med. 1998 Jul 20;188(2):373-86 PMID: 9670049
  10. Heteroclitic immunization induces tumor immunity.
    J Exp Med. 1998 Nov 2;188(9):1553-61 PMID: 9802967
  11. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling.
    Immunity. 1998 Dec;9(6):817-26 PMID: 9881972
  12. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs.
    J Exp Med. 1999 Feb 1;189(3):447-50 PMID: 9927506
  13. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7 PMID: 10077623
  14. A new era for cancer immunotherapy based on the genes that encode cancer antigens.
    Immunity. 1999 Mar;10(3):281-7 PMID: 10204484
  15. Divergent changes in the sensitivity of maturing T cells to structurally related ligands underlies formation of a useful T cell repertoire.
    Immunity. 1999 Mar;10(3):367-76 PMID: 10204492
  16. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.
    Semin Cancer Biol. 1999 Apr;9(2):67-81 PMID: 10202129
  17. Inducing autoimmune disease to treat cancer.
    Proc Natl Acad Sci U S A. 1999 May 11;96(10):5340-2 PMID: 10318881
  18. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
    Nat Med. 1999 Jun;5(6):677-85 PMID: 10371507
  19. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
    Clin Cancer Res. 1999 Jun;5(6):1331-8 PMID: 10389916
  20. The immunological synapse: a molecular machine controlling T cell activation.
    Science. 1999 Jul 9;285(5425):221-7 PMID: 10398592
  21. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    J Exp Med. 1999 Aug 2;190(3):355-66 PMID: 10430624
  22. Immune selection after antigen-specific immunotherapy of melanoma.
    Surgery. 1999 Aug;126(2):112-20 PMID: 10455872
  23. Human tumor antigens recognized by T lymphocytes.
    J Exp Med. 1996 Mar 1;183(3):725-9 PMID: 8642276
  24. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease.
    J Exp Med. 2000 Mar 6;191(5):795-804 PMID: 10704461
  25. Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.
    Int J Cancer. 2000 Mar 15;85(6):829-38 PMID: 10709104
  26. Immunobiology of dendritic cells.
    Annu Rev Immunol. 2000;18:767-811 PMID: 10837075
  27. In vivo generation of human dendritic cell subsets by Flt3 ligand.
    Blood. 2000 Aug 1;96(3):878-84 PMID: 10910900
  28. Eradication of established tumors by CD8+ T cell adoptive immunotherapy.
    Immunity. 2000 Aug;13(2):265-76 PMID: 10981969
  29. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.
    J Clin Oncol. 2000 Dec 1;18(23):3883-93 PMID: 11099317
  30. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    J Exp Med. 2000 Dec 4;192(11):1637-44 PMID: 11104805
  31. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex.
    Immunity. 2000 Oct;13(4):529-38 PMID: 11070171
  32. Tolerance and autoimmunity.
    N Engl J Med. 2001 Mar 1;344(9):655-64 PMID: 11228281
  33. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
    J Immunol. 2001 Feb 15;166(4):2863-70 PMID: 11160355
  34. Structural and functional consequences of altering a peptide MHC anchor residue.
    J Immunol. 2001 Mar 1;166(5):3345-54 PMID: 11207290
  35. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Cancer Res. 2001 May 1;61(9):3725-34 PMID: 11325845
  36. Progress in human tumour immunology and immunotherapy.
    Nature. 2001 May 17;411(6835):380-4 PMID: 11357146
  37. Antigen decoding by T lymphocytes: from synapses to fate determination.
    Nat Immunol. 2001 Jun;2(6):487-92 PMID: 11376334
  38. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
    Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809-14 PMID: 11427731
  39. Self-nonself discrimination by T cells.
    Science. 1990 Jun 15;248(4961):1369-73 PMID: 1972594
  40. Peripheral selection of the T cell repertoire.
    Science. 1991 Mar 8;251(4998):1225-8 PMID: 1900951
  41. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells.
    Cell. 1993 Dec 17;75(6):1157-67 PMID: 7505204
  42. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
    J Natl Cancer Inst. 1995 Jul 5;87(13):982-90 PMID: 7629885
  43. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.
    J Exp Med. 1995 Sep 1;182(3):689-98 PMID: 7544395
  44. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.
    Int J Cancer. 1995 Dec 11;63(6):883-5 PMID: 8847150
  45. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.
    Nat Med. 1996 Jan;2(1):52-8 PMID: 8564842
  46. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4 PMID: 8859727
  47. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.
    J Exp Med. 1996 Nov 1;184(5):1953-62 PMID: 8920882
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
DOI
10.1073/pnas.171326398
Email
sriddell@fhcrc.org
Published
2001-07-31
Pages
8933-5
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC55350
Subset
IM
Corrections
CommentOn
PMID: 11427731
External Links
PubMed source DOI: 10.1073/pnas.171326398 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2